Stonegate Capital Partners Updates Coverage on OS Therapies Inc.: Regulatory Clarity and Key Catalysts Ahead

Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), emphasizing significant regulatory and commercialization advancements for its lead candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma. The company has shifted from Phase 2b-supported planning toward a more defined global approval pathway, with key changes including greater regulatory clarity from the European Medicines Agency (EMA) and Australia's Therapeutic Goods Administration (TGA).

According to the update, the EMA has initiated a rolling review of the OST-HER2 Conditional Marketing Authorization dossier, while the EMA and TGA have aligned on 3-year overall survival (OS) as the approvable efficacy endpoint. Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, transitioning the investment narrative from early proof-of-concept to execution across a dense 2026 catalyst calendar.

Key milestones outlined include 2.5-year OS data in mid-second quarter 2026, meetings with the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter of 2026, Phase 3 initiation in Australia in the third quarter of 2026, 3-year OS data in early fourth quarter 2026, and a potential EMA Conditional Marketing Authorization decision in the fourth quarter of 2026.

Stonegate notes that regulatory clarity is the core value inflection, with the EMA rolling review, TGA endpoint alignment, MHRA Advanced Therapy Medicinal Product (ATMP) designation, and upcoming FDA/MHRA meetings shifting OST-HER2 from Phase 2b validation toward an executable global approval pathway. Survival data remain the key catalyst stack, as the mid-2026 2.5-year OS data and early fourth quarter 2026 3-year OS data should determine whether the company can complete the EMA submission and sustain accelerated-access momentum.

Financing and Priority Review Voucher (PRV) optionality are seen as bridges to the regulatory window. The company raised $5.25 million, with an expected $4.0 million in non-dilutive funding to support the 2026 catalysts. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million.

For more details, the full announcement is available here.